Diagonal Therapeutics
PrivateLast Round
Series B
Jan 8, 2026
Total Funding Raised
$253M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Diagonal Therapeutics is a biotechnology company that discovers and develops agonist antibodies using a proprietary platform to address the root causes of severe diseases such as hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Diagonal Therapeutics Comparables
Compare Diagonal Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Vaderis Therapeutics | 81% | |
| Tectonic Therapeutic | 79% | |
| AltruBio | 71% | |
Diagonal Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jan 8, 2026 | ||||
| Series A | Apr 3, 2024 |
Key People
Founding team and executive leadership
Diagonal Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| EcoR1 Capital | Series B |
| Janus Henderson Group | Series B |
| RA Capital Advisors | Series A |
| Balyasny Asset Management L.P. | Series B |
| RA Capital Management | Series A, Series B |
| VF Partners | Series A |
| Deep Track Capital | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 1, 2026
Grew 25% QoQ, from 28 to 35 employees.
- Jan 9, 2026
Paulina Hill joins the Board of Directors.
Diagonal Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Diagonal Therapeutics's valuation, stock price, and market status.